Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced positive top-line Phase II study results for its novel ...

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

All law enforcement agencies would be required to follow an active shooter training program developed by the Law enforcement ...

Texas A&M Forest Service is highlighting how Texans can prevent wildfires and prepare for when they occur during Wildfire Awareness Month, ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

First responders from across the region spent this week in Bristol, Virginia, preparing and training for a possible active ...

A new pilot study reveals that psilocybin—the compound found in psychedelic mushrooms—may significantly improve mood, ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...